Seminars in Oncology
Volume 30, Issue 1 , Pages 72-78 , February 2003

Recurrent small cell lung cancer: Update

References 

  1. Giaccone G, Donadio M, Bonardi G, et al.  Teniposide in the treatment of small-cell lung cancer: The influence of prior chemotherapy. J Clin Oncol. 1988;6:1264–1270
  2. Ardizzoni A, Hansen H, Dombernowsky P, et al.  Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. J Clin Oncol. 1997;15:2090–2096
  3. Eckardt J, Depierre A, Ardizzoni A, et al.  Pooled analysis of topotecan (T) in the second-line treatment of patients (pts) with sensitive small cell lung cancer (SCLC). In: Proc Am Soc Clin Oncol. 16:1997;p. 452a; (abstr 1624)
  4. Perez-Soler R, Glisson BS, Lee JS, et al.  Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol. 1996;14:2785–2790
  5. Masuda N, Fukuoka M, Kusunoki Y, et al.  CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992;10:1225–1229
  6. Chevalier TL, Ibrahim N, Chomy P, et al.  A phase II study of irinotecan (CPT-11) in patients (pts) with small cell lung cancer (SCLC) progressing after initial response to first-line chemotherapy (CT). Proc Am Soc Clin Oncol. 1997;16:450a; (abstr 1617)
  7. DeVore RF, Blanke CD, Denham CA, et al.  Phase II study of irinotecan (CPT-11) in patients with previously treated small-cell lung cancer (SCLC). Proc Am Soc Clin Oncol. 1998;17:451a; (abstr 1736)
  8. Smyth JF, Smith IE, Sessa C, et al.  Docetaxel shows antitumor activity in second-line SCLC. Eur J Cancer. 1994;30A:1058–1060
  9. Samantas E, Klamouris C, Kalofonos H, et al.  Phase II study with docetaxel in pretreated patients with small cell lung cancer. Ann Oncol. 1998;9:104; (abstr 396)
  10. Smit EF, Fokkema E, Biesma B, et al.  A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer. 1998;77:347–351
  11. Van der Lee I, Postmus P, Smit E, et al.  The activity of gemcitabine in patients with resistant small cell lung cancer (SCLC): A phase II study. Proc Am Soc Clin Oncol. 1999;18:476a; (abstr 1835)
  12. Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe M, et al.  Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. Eur J Cancer. 1993;29A:1720–1722
  13. Furuse K, Kubota K, Kawahara M, et al.  Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Oncology. 1996;53:169–172
  14. von Pawel J, Schiller JH, Shepherd FA, et al.  Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17:658–674
  15. von Pawel J, Gatzemeier U, Pujol JL, et al.  Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol. 2001;19:1743–1749
  16. Masuda N, Matsui K, Negoro S, et al.  Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1998;16:3329–3334
  17. Ando M, Kobayshi K, Yoshioka H, et al.  Weekly administration of irinotecan (CPT-11) plus cisplatin (CDDP) for refractory or relapsed small cell lung cancer (SCLC). Proc Am Soc Clin Oncol. 2001;20:319a; (abstr 1273)
  18. Fujita A, Takabatake H, Tagaki S, et al.  Combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support for the treatment of refractory or relapsed small-cell lung cancer. Oncology. 2000;59:105–109
  19. Ardizzoni A, Manegold C, Gaafar R, et al.  Combination chemotherapy with cisplatin and topotecan as second-line treatment of sensitive (S) and refractory (R) small cell lung cancer (SCLC): An EORTC LCG phase II study. Proc Am Soc Clin Oncol. 1999;18:471a; (abstr 1817)
  20. Groen HJM, Fokkema E, Biesma B, et al.  Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: A non-cross-resistant schedule. J Clin Oncol. 1999;17:927–932
  21. Sonpavde G, Ansari R, Walker P, et al.  Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: A Hoosier Oncology Group trial. Am J Clin Oncol. 2000;23:68–70
  22. Domine M, Gonzalez J, Larriba S, et al.  Gemcitabine and paclitaxel as second line treatment in small cell lung cancer (SCLC). A multicentric phase II study. Proc Am Soc Clin Oncol. 2001;20:317a; (abstr 1263)
  23. Kosmas C, Tsavaris NB, Malamos NA, et al.  Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer. J Clin Oncol. 2001;19:119–126
  24. Postmus PE, Berendsen HN, Van Zandwijk N, et al.  Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol. 1987;23:1409–1411
  25. Cuttitta F, Carney DC, Mulshine J, et al.  Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature. 1985;316:823–826
  26. Kelley MJ, Linnoila I, Avis IL, et al.  Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest. 1997;112:256–261
  27. Roy DC, Ouellet S, Le Houiller C, et al.  Elimination of neuroblastoma and small cell lung cancer cells with an anti-NCAM immunotoxin. J Natl Cancer Inst. 1996;88:1136–1145
  28. Lynch TJ, Lambert JM, Coral F, et al.  Immunotoxin therapy of small-cell lung cancer: A phase I study of N901-blocked ricin. J Clin Oncol. 1997;15:723–734
  29. Fidias P, Lynch TJ. Targeted therapy of SCLC using N901-blocked ricin. Clin Lung Cancer. 2002;3:219–222
  30. Fossella FV, Tolcher A, Elliott M, et al.  Phase I trial of the monoclonal antibody conjugate, BB-10901, for relapsed/refractory small cell lung cancer (SCLC) and other neuroendocrine (NE) tumors. Proc Am Soc Clin Oncol. 2002;21:309a; (abstr 1232)
  31. Rudin C, Otterson GA, George CM, et al.  A phase I/II trial of genasense and paclitaxel in chemorefractory small cell lung cancer. Proc Am Soc Clin Oncol. 2001;20:322a; (abstr 1283)
  32. Gamou S, Hunts J, Harigai H, et al.  Molecular evidence for the lack of epidermal growth factor receptor gene expression in small cell lung carcinoma cells. Cancer Res. 1987;47:2668–2673
  33. Haeder M, Rotsch M, Bepler G, et al.  Epidermal growth factor receptor expression in human lung cancer cell lines. Cancer Res. 1988;48:1132–1136
  34. Kaseda S, Ueda M, Ozawa S, et al.  Expression of epidermal growth factor receptors in four histologic cell types of lung cancer. J Surg Oncol. 1989;42:16–20
  35. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res. 2001;7:2958–2970
  36. Fukuoka M, Yano S, Giaccone G, et al.  Final results from a phase III trial of 2D1839 (‘Iressa’) for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol. 2002;21:298a; (abstr 1188)
  37. Kris M, Natale R, Herbst R, et al.  A phase II trial of ZD1839 (Iressa) in advanced non–small cell lung cancer (NSCLC) who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol. 2002;21:292a; (abstr 1166)
  38. Ciardello F, Caputo R, Bianco R, et al.  Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 2000;6:2053–2063
  39. Sirotnak F, Zakowski M, Miller V, et al.  Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 2000;6:4885–4892

☆ Address reprint requests to Bonnie S. Glisson, MD, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 432, Houston, TX 77030-4009.

PII: S0093-7754(03)70044-X

doi: 10.1053/sonc.2003.50014

Seminars in Oncology
Volume 30, Issue 1 , Pages 72-78 , February 2003

Article Tools